Tags

Type your tag names separated by a space and hit enter

Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme.
Curr Opin Mol Ther 2010; 12(6):741-54CO

Abstract

Celldex Therapeutics is developing rindopepimut (CDX-110), a 14-mer injectable peptide vaccine for the potential treatment of glioblastoma multiforme (GBM). Rindopepimut specifically targets a novel junctional epitope of the EGFR deletion mutant EGFRvIII, which is a constitutively active receptor that is expressed in approximately 60 to 70% of patients with GBM. EGFRvIII expression is correlated with worse prognosis and reduced overall survival. Importantly, EGFRvIII is not expressed in normal brain tissue, making it an excellent therapeutic target. Preclinical studies demonstrated lasting tumor regression and increased survival times, as well as efficient generation of EGFRvIII-specific humoral and cellular immune responses, in animals expressing EGFRvIII and vaccinated with rindopepimut. Phase I and II clinical trials in patients with GBM demonstrated significantly increased median time to progression and overall survival time in those vaccinated with rindopepimut compared with matched historical controls. Only limited side effects have been observed in patients. Given these results, rindopepimut is an extremely promising therapy for patients with GBM. Phase I and II clinical trials in patients with GBM were ongoing at the time of publication. In the future, it may be beneficial to combine rindopepimut with other treatment modalities to further prolong survival.

Authors+Show Affiliations

Stanford University, 300 Pasteur Drive, Edwards R213, Stanford, CA 94305, USA.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21154166

Citation

Del Vecchio, Catherine A., and Albert J. Wong. "Rindopepimut, a 14-mer Injectable Peptide Vaccine Against EGFRvIII for the Potential Treatment of Glioblastoma Multiforme." Current Opinion in Molecular Therapeutics, vol. 12, no. 6, 2010, pp. 741-54.
Del Vecchio CA, Wong AJ. Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme. Curr Opin Mol Ther. 2010;12(6):741-54.
Del Vecchio, C. A., & Wong, A. J. (2010). Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme. Current Opinion in Molecular Therapeutics, 12(6), pp. 741-54.
Del Vecchio CA, Wong AJ. Rindopepimut, a 14-mer Injectable Peptide Vaccine Against EGFRvIII for the Potential Treatment of Glioblastoma Multiforme. Curr Opin Mol Ther. 2010;12(6):741-54. PubMed PMID: 21154166.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme. AU - Del Vecchio,Catherine A, AU - Wong,Albert J, PY - 2010/12/15/entrez PY - 2010/12/15/pubmed PY - 2011/5/20/medline SP - 741 EP - 54 JF - Current opinion in molecular therapeutics JO - Curr. Opin. Mol. Ther. VL - 12 IS - 6 N2 - Celldex Therapeutics is developing rindopepimut (CDX-110), a 14-mer injectable peptide vaccine for the potential treatment of glioblastoma multiforme (GBM). Rindopepimut specifically targets a novel junctional epitope of the EGFR deletion mutant EGFRvIII, which is a constitutively active receptor that is expressed in approximately 60 to 70% of patients with GBM. EGFRvIII expression is correlated with worse prognosis and reduced overall survival. Importantly, EGFRvIII is not expressed in normal brain tissue, making it an excellent therapeutic target. Preclinical studies demonstrated lasting tumor regression and increased survival times, as well as efficient generation of EGFRvIII-specific humoral and cellular immune responses, in animals expressing EGFRvIII and vaccinated with rindopepimut. Phase I and II clinical trials in patients with GBM demonstrated significantly increased median time to progression and overall survival time in those vaccinated with rindopepimut compared with matched historical controls. Only limited side effects have been observed in patients. Given these results, rindopepimut is an extremely promising therapy for patients with GBM. Phase I and II clinical trials in patients with GBM were ongoing at the time of publication. In the future, it may be beneficial to combine rindopepimut with other treatment modalities to further prolong survival. SN - 2040-3445 UR - https://www.unboundmedicine.com/medline/citation/21154166/Rindopepimut,_a_14-mer_injectable_peptide_vaccine_against_EGFRvIII_for_the_potential_treatment_of_glioblastoma_multiforme L2 - http://www.diseaseinfosearch.org/result/3076 DB - PRIME DP - Unbound Medicine ER -